ALLAKOS INC (ALLK) Stock News
NASDAQ:ALLK - Nasdaq - US01671P1003 - Common Stock - Currency: USD
ALLK Latest News, Press Relases and Analysis
Why Is Allakos Stock Plunging On Monday?
Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 million in estimated costs.
ALLK Stock Earnings: Allakos Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Allakos (NASDAQ:ALLK) just reported results for the second quarter of 2024.Alla...
ALLK Stock Earnings: Allakos Beats EPS for Q2 2024
ALLK stock results show that Allakos beat analyst estimates for earnings per share the second quarter of 2024.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, RDFN, ALLK on Behalf of Shareholders
ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing...
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company that has been developing...
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade
The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring
– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore...
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allakos Inc. (NASDAQ: ALLK)...
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the...
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was...
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the...